Back grey_arrow_rt.gif
 
 
Gilead Patent Filing for Viread in India
 
 
  Gilead filed a patent application for Viread (tenofovir disoproxil fumarate) in India, and we expect this patent to issue shortly.
 
We are also pursuing a broad policy of non-exclusive, voluntary licensing under this patent to generic manufacturers in India for the local Indian market as well as provision for manufacturers to export product to the 97 developing world countries included in Gileadfs access program. We are in initial discussions with a number of interested parties. The specifics of these plans have not been finalized, and we will provide more details as soon as possible. We believe that multiple manufacturers will ensure competitive prices and the broadest access possible in these least developed countries.
 
We disagree with statements that Viread should not be patented; we believe that Viread represents innovation and is patentable under Indian law. We will use this patent responsibly, and will not block access to our medication in India or in other resource-limited countries where the HIV epidemic has hit the hardest.
 
We remain committed to completing registrational filings in all countries of the companyfs access program. Applications in 61 countries have been completed, and the remaining filings will be submitted before year end.
 
Amy Flood
Director, Public Affairs
Gilead Sciences, Inc.
Tel: 650-522-5643
Fax: 650-522-5853
aflood@gilead.com
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org